Cargando…
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365369/ https://www.ncbi.nlm.nih.gov/pubmed/34980600 http://dx.doi.org/10.1158/1078-0432.CCR-21-1992 |
_version_ | 1784765330449498112 |
---|---|
author | Cruz-Duarte, Raquel Rebelo de Almeida, Cátia Negrão, Magda Fernandes, Afonso Borralho, Paula Sobral, Daniel Gallego-Paez, Lina M. Machado, Daniel Gramaça, João Vílchez, José Xavier, Ana T. Ferreira, Miguel Godinho Miranda, Ana R. Mansinho, Helder Brito, Maria J. Pacheco, Teresa R. Abreu, Catarina Lucia-Costa, Ana Mansinho, André Fior, Rita Costa, Luís Martins, Marta |
author_facet | Cruz-Duarte, Raquel Rebelo de Almeida, Cátia Negrão, Magda Fernandes, Afonso Borralho, Paula Sobral, Daniel Gallego-Paez, Lina M. Machado, Daniel Gramaça, João Vílchez, José Xavier, Ana T. Ferreira, Miguel Godinho Miranda, Ana R. Mansinho, Helder Brito, Maria J. Pacheco, Teresa R. Abreu, Catarina Lucia-Costa, Ana Mansinho, André Fior, Rita Costa, Luís Martins, Marta |
author_sort | Cruz-Duarte, Raquel |
collection | PubMed |
description | PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as well as to develop new therapeutic approaches to overcome cetuximab resistance. EXPERIMENTAL DESIGN: We evaluated the value of EGFR effector phospholipase C gamma 1 (PLCγ1) in predicting cetuximab responses, by analyzing progression-free survival (PFS) of a multicentric retrospective cohort of 94 treated patients with mCRC (log-rank test and Cox regression model). Furthermore, we used in vitro and zebrafish xenotransplant models to identify and target the mechanism behind PLCγ1-mediated resistance to cetuximab. RESULTS: In this study, levels of PLCγ1 were found increased in RAS WT tumors and were able to predict cetuximab responses in clinical samples and in vitro and in vivo models. Mechanistically, PLCγ1 expression was found to bypass cetuximab-dependent EGFR inhibition by activating ERK and AKT pathways. This novel resistance mechanism involves a noncatalytic role of PLCγ1 SH2 tandem domains in the propagation of downstream signaling via SH2-containing protein tyrosine phosphatase 2 (SHP2). Accordingly, SHP2 inhibition sensitizes PLCγ1-resistant cells to cetuximab. CONCLUSIONS: Our discoveries reveal the potential of PLCγ1 as a predictive biomarker for cetuximab responses and suggest an alternative therapeutic approach to circumvent PLCγ1-mediated resistance to cetuximab in patients with RAS WT mCRC. In this way, this work contributes to the development of novel strategies in the medical management and treatment of patients with mCRC. |
format | Online Article Text |
id | pubmed-9365369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93653692023-01-05 Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer Cruz-Duarte, Raquel Rebelo de Almeida, Cátia Negrão, Magda Fernandes, Afonso Borralho, Paula Sobral, Daniel Gallego-Paez, Lina M. Machado, Daniel Gramaça, João Vílchez, José Xavier, Ana T. Ferreira, Miguel Godinho Miranda, Ana R. Mansinho, Helder Brito, Maria J. Pacheco, Teresa R. Abreu, Catarina Lucia-Costa, Ana Mansinho, André Fior, Rita Costa, Luís Martins, Marta Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as well as to develop new therapeutic approaches to overcome cetuximab resistance. EXPERIMENTAL DESIGN: We evaluated the value of EGFR effector phospholipase C gamma 1 (PLCγ1) in predicting cetuximab responses, by analyzing progression-free survival (PFS) of a multicentric retrospective cohort of 94 treated patients with mCRC (log-rank test and Cox regression model). Furthermore, we used in vitro and zebrafish xenotransplant models to identify and target the mechanism behind PLCγ1-mediated resistance to cetuximab. RESULTS: In this study, levels of PLCγ1 were found increased in RAS WT tumors and were able to predict cetuximab responses in clinical samples and in vitro and in vivo models. Mechanistically, PLCγ1 expression was found to bypass cetuximab-dependent EGFR inhibition by activating ERK and AKT pathways. This novel resistance mechanism involves a noncatalytic role of PLCγ1 SH2 tandem domains in the propagation of downstream signaling via SH2-containing protein tyrosine phosphatase 2 (SHP2). Accordingly, SHP2 inhibition sensitizes PLCγ1-resistant cells to cetuximab. CONCLUSIONS: Our discoveries reveal the potential of PLCγ1 as a predictive biomarker for cetuximab responses and suggest an alternative therapeutic approach to circumvent PLCγ1-mediated resistance to cetuximab in patients with RAS WT mCRC. In this way, this work contributes to the development of novel strategies in the medical management and treatment of patients with mCRC. American Association for Cancer Research 2022-03-15 2022-03-14 /pmc/articles/PMC9365369/ /pubmed/34980600 http://dx.doi.org/10.1158/1078-0432.CCR-21-1992 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Translational Cancer Mechanisms and Therapy Cruz-Duarte, Raquel Rebelo de Almeida, Cátia Negrão, Magda Fernandes, Afonso Borralho, Paula Sobral, Daniel Gallego-Paez, Lina M. Machado, Daniel Gramaça, João Vílchez, José Xavier, Ana T. Ferreira, Miguel Godinho Miranda, Ana R. Mansinho, Helder Brito, Maria J. Pacheco, Teresa R. Abreu, Catarina Lucia-Costa, Ana Mansinho, André Fior, Rita Costa, Luís Martins, Marta Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title | Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title_full | Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title_fullStr | Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title_full_unstemmed | Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title_short | Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer |
title_sort | predictive and therapeutic implications of a novel plcγ1/shp2-driven mechanism of cetuximab resistance in metastatic colorectal cancer |
topic | Translational Cancer Mechanisms and Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365369/ https://www.ncbi.nlm.nih.gov/pubmed/34980600 http://dx.doi.org/10.1158/1078-0432.CCR-21-1992 |
work_keys_str_mv | AT cruzduarteraquel predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT rebelodealmeidacatia predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT negraomagda predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT fernandesafonso predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT borralhopaula predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT sobraldaniel predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT gallegopaezlinam predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT machadodaniel predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT gramacajoao predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT vilchezjose predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT xavieranat predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT ferreiramiguelgodinho predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT mirandaanar predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT mansinhohelder predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT britomariaj predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT pachecoteresar predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT abreucatarina predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT luciacostaana predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT mansinhoandre predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT fiorrita predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT costaluis predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer AT martinsmarta predictiveandtherapeuticimplicationsofanovelplcg1shp2drivenmechanismofcetuximabresistanceinmetastaticcolorectalcancer |